Long-Term Severe In Vitro Hypoxia Exposure Enhances the Vascularization Potential of Human Adipose Tissue-Derived Stromal Vascular Fraction Cell Engineered Tissues.
engineered tissues
hypoxic culture
in vivo angiogenesis
stromal vascular fraction cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
24 Jul 2021
24 Jul 2021
Historique:
received:
31
05
2021
revised:
21
07
2021
accepted:
22
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
24
8
2021
Statut:
epublish
Résumé
The therapeutic potential of mesenchymal stromal/stem cells (MSC) for treating cardiac ischemia strongly depends on their paracrine-mediated effects and their engraftment capacity in a hostile environment such as the infarcted myocardium. Adipose tissue-derived stromal vascular fraction (SVF) cells are a mixed population composed mainly of MSC and vascular cells, well known for their high angiogenic potential. A previous study showed that the angiogenic potential of SVF cells was further increased following their in vitro organization in an engineered tissue (patch) after perfusion-based bioreactor culture. This study aimed to investigate the possible changes in the cellular SVF composition, in vivo angiogenic potential, as well as engraftment capability upon in vitro culture in harsh hypoxia conditions. This mimics the possible delayed vascularization of the patch upon implantation in a low perfused myocardium. To this purpose, human SVF cells were seeded on a collagen sponge, cultured for 5 days in a perfusion-based bioreactor under normoxia or hypoxia (21% and <1% of oxygen tension, respectively) and subcutaneously implanted in nude rats for 3 and 28 days. Compared to ambient condition culture, hypoxic tension did not alter the SVF composition in vitro, showing similar numbers of MSC as well as endothelial and mural cells. Nevertheless, in vitro hypoxic culture significantly increased the release of vascular endothelial growth factor (
Identifiants
pubmed: 34360685
pii: ijms22157920
doi: 10.3390/ijms22157920
pmc: PMC8348696
pii:
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Am Coll Cardiol. 2009 Dec 8;54(24):2277-86
pubmed: 19958962
Stem Cells. 2009 Aug;27(8):1976-86
pubmed: 19544425
Eur Heart J. 2007 Nov;28(21):2667-77
pubmed: 17933755
Oncotarget. 2017 May 10;8(39):65064-65076
pubmed: 29029412
Am J Cardiol. 2004 Jul 1;94(1):92-5
pubmed: 15219514
Nat Protoc. 2008;3(4):719-38
pubmed: 18388955
J Am Coll Cardiol. 2012 Jan 31;59(5):539-40
pubmed: 22281257
Cytotherapy. 2011 Mar;13(3):318-28
pubmed: 20795759
ScientificWorldJournal. 2013 Aug 27;2013:632972
pubmed: 24068884
J Cardiothorac Surg. 2011 Mar 31;6:43
pubmed: 21453457
Stem Cell Res Ther. 2019 Nov 26;10(1):348
pubmed: 31771642
Biotechnol Bioeng. 2016 Jan;113(1):226-36
pubmed: 26126766
PLoS One. 2015 Sep 18;10(9):e0138477
pubmed: 26380983
Front Immunol. 2018 Dec 04;9:2837
pubmed: 30564236
Sci Rep. 2017 Oct 27;7(1):14252
pubmed: 29079730
Cell Transplant. 2014 Jan;23(1):87-96
pubmed: 23127387
Stem Cells Dev. 2013 May 15;22(10):1614-23
pubmed: 23282141
Tissue Eng. 2005 Sep-Oct;11(9-10):1421-8
pubmed: 16259597
Biotechnol Bioeng. 2019 Jan;116(1):132-142
pubmed: 30171703
Biores Open Access. 2014 Aug 1;3(4):137-49
pubmed: 25126478
Wound Repair Regen. 2009 Jul-Aug;17(4):540-7
pubmed: 19614919
J Korean Med Sci. 2014 Jan;29(1):23-31
pubmed: 24431901
Circ Res. 2014 Apr 11;114(8):1302-10
pubmed: 24565698
Stem Cells. 2003;21(3):337-47
pubmed: 12743328
Life Sci. 2007 Sep 8;81(13):1042-9
pubmed: 17854840
Cardiovasc Res. 2009 Sep 1;83(4):757-67
pubmed: 19505931
Nat Rev Cardiol. 2009 Aug;6(8):515-23
pubmed: 19528962
J Am Heart Assoc. 2017 May 3;6(5):
pubmed: 28468789